Author:
Stewart Aaron,Yates Ian,Mudie Deanna,Pivette Perrine,Goodwin Aaron,Sarmiento Alyssa,Winter Marcus,Morgen Michael,Vodak David
Reference49 articles.
1. Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma;Bodiford;Onco Targets Ther,2014
2. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101);Steele;Pharmacology,2010
3. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability;Amidon;Pharm Res,1995
4. Purely in silico BCS classification: science based quality standards for the world’s drugs;Dahan;Mol Pharm,2013
5. Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development;Wolk;Drug Des Devel Ther,2014
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献